Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Status Epilepticus Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Status Epilepticus Overview | 8 | 1 |
| Pipeline Products for Status Epilepticus Comparative Analysis | 9 | 1 |
| Status Epilepticus Therapeutics under Development by Companies | 10 | 1 |
| Status Epilepticus Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Status Epilepticus Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Status Epilepticus Products under Development by Companies | 15 | 1 |
| Status Epilepticus Products under Investigation by Universities/Institutes | 16 | 1 |
| Status Epilepticus Companies Involved in Therapeutics Development | 17 | 3 |
| Marinus Pharmaceuticals, Inc. | 17 | 1 |
| Sage Therapeutics, Inc. | 18 | 1 |
| Shire Plc | 19 | 1 |
| Status Epilepticus Therapeutics Assessment | 20 | 9 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Target | 21 | 2 |
| Assessment by Mechanism of Action | 23 | 2 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Drug Profiles | 29 | 21 |
| AMPX-0079 Drug Profile | 29 | 1 |
| fosphenytoin sodium Drug Profile | 30 | 1 |
| ganaxolone Drug Profile | 31 | 5 |
| LSPGR-1 Drug Profile | 36 | 1 |
| midazolam hydrochloride Drug Profile | 37 | 1 |
| SAGE-217 Drug Profile | 38 | 2 |
| SAGE-689 Drug Profile | 40 | 1 |
| sepranolone Drug Profile | 41 | 7 |
| Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus Drug Profile | 48 | 1 |
| TG-4155 Drug Profile | 49 | 1 |
| Status Epilepticus Dormant Projects | 50 | 1 |
| Status Epilepticus Product Development Milestones | 51 | 13 |
| Featured News &Press Releases | 51 | 1 |
| Jun 22, 2016: Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV | 51 | 1 |
| Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures | 51 | 1 |
| Apr 19, 2016: Marinus Pharmaceuticals Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus | 52 | 1 |
| Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting | 53 | 2 |
| Apr 15, 2016: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus | 55 | 1 |
| Apr 12, 2016: Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting | 55 | 1 |
| Mar 03, 2016: Sage Therapeutics to Present SAGE-547 Clinical Data and SRSE Health Economic Data in Five Abstracts at the American Academy of Neurology 2016 Annual Meeting | 56 | 1 |
| Dec 15, 2015: SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547 | 56 | 1 |
| Dec 02, 2015: SAGE to Present Poster Presentations on SAGE-547 at the American Epilepsy Society 69th Annual Meeting | 57 | 1 |
| Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus | 58 | 1 |
| Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus | 58 | 1 |
| Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression | 59 | 1 |
| May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus | 60 | 2 |
| Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547 | 62 | 1 |
| Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus | 63 | 1 |
| Appendix | 64 | 2 |
| Methodology | 64 | 1 |
| Coverage | 64 | 1 |
| Secondary Research | 64 | 1 |
| Primary Research | 64 | 1 |
| Expert Panel Validation | 64 | 1 |
| Contact Us | 64 | 1 |
| Disclaimer | 65 | 1 |